Radiotherapy plus immune checkpoint blockade in PD(L)-1-resistant metastatic NSCLC. Ochoa-de-Olza M, Bourhis J, Coukos G, Herrera FG, et al. Lancet Oncol 2022;23:e157.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Ochoa-de-Olza M, Bourhis J, Coukos G, Herrera FG, et al. Radiotherapy plus immune checkpoint blockade in PD(L)-1-resistant metastatic NSCLC. Lancet Oncol 2022;23:e157.
PMID: 35358457